<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946929</url>
  </required_header>
  <id_info>
    <org_study_id>KY2021-083</org_study_id>
    <nct_id>NCT04946929</nct_id>
  </id_info>
  <brief_title>Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT)</brief_title>
  <acronym>Tip-HAT</acronym>
  <official_title>Determine the Safety/Efficacy of Ticagrelor in Post-transplant Patients With Hepatic Artery Thrombosis (HAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic artery thrombosis (HAT) represents a major cause of graft loss and mortality after&#xD;
      Pediatric liver transplantation. Ticagrelor (a new reversible inhibitor of P2Y12 receptor&#xD;
      with faster onset of action and greater platelet inhibition) was used to treat patients with&#xD;
      pediatric post-transplant hepatic artery thrombosis (HAT) compared to low molecular weight&#xD;
      heparin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In pediatric patients with post-transplant hepatic artery thrombosis (HAT) , low molecular&#xD;
      weight heparin is a commonly used method. Ticagrelor, a direct-acting and reversible ADP&#xD;
      receptor antagonist, is now the most commonly used ADP receptor antagonist in the treatment&#xD;
      of coronary diseases. Compared to its predecessor clopidogrel, the pharmacokinetic profil of&#xD;
      ticagrelor is more predictable, demonstrating a faster onset of action and a more consistent&#xD;
      platelet inhibition. However, because of the excellent antithrombotic effect and increased&#xD;
      bleeding potential, it is recommended that major bleeding, such as OPCAB or CABG surgery, be&#xD;
      expected with a high probability, and in case of fatal surgery, the drug should be&#xD;
      discontinued for 5 days. The present study is to evaluate the safety and efficacy of&#xD;
      Ticagrelor in pediatirc receipt with post-operative HAT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast-Enhanced Ultrasonography-Based Hepatic Perfusion Index</measure>
    <time_frame>3 months</time_frame>
    <description>The peak systolic maximum velocity (Vmax) of the HA, and HA resistive index (HARI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High on-treatment platelet reactivity (HPR)</measure>
    <time_frame>Two hours after the injection of either active drug or placebo</time_frame>
    <description>HPR defined as platelet reactivity index (PRI) â‰¥50% using VASP analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative major bleeding event</measure>
    <time_frame>within 72 hours after operation</time_frame>
    <description>post-operative major bleeding defined as HAT related bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatic Artery Thrombosis</condition>
  <condition>Liver Transplant; Complications</condition>
  <condition>Pediatric Disease</condition>
  <arm_group>
    <arm_group_label>Ticagrelor, 2-3mg/kg, 12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-3mg/kg, q12h, p.o. for 2w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low molecular weight heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>half amount low molecular weight heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor Oral Tablet [Brilinta]</intervention_name>
    <description>Ticagrelor, 2-3mg/kg, 12h, p.o.</description>
    <arm_group_label>Ticagrelor, 2-3mg/kg, 12h</arm_group_label>
    <other_name>Ticagrelor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low molecular weight heparin</intervention_name>
    <description>half amount low molecular weight heparin</description>
    <arm_group_label>low molecular weight heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age from 2 months to 5 years old.&#xD;
&#xD;
          -  voluntary participation in clinical trials, and informed consent;&#xD;
&#xD;
          -  Contrast- Enhanced Ultrasonography proved HAT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of sensitivity to study medications or any of their excipients&#xD;
&#xD;
          -  Renal failure (eGFR &lt;30 or requiring dialysis)&#xD;
&#xD;
          -  A known bleeding diathesis, hemostatic or coagulation disorder, or prior major&#xD;
             bleeding&#xD;
&#xD;
          -  Prior stroke&#xD;
&#xD;
          -  Active pathological bleeding&#xD;
&#xD;
          -  History of intracranial haemorrhage&#xD;
&#xD;
          -  Life expectancy &lt;12 months based on investigator's judgement&#xD;
&#xD;
          -  Patients considered to be at risk of bradycardic events (e.g., known sick sinus&#xD;
             syndrome or second or third degree atrioventricular [AV)] block) unless already&#xD;
             treated with a permanent pacemaker&#xD;
&#xD;
          -  Anemia (hematocrit &lt; 27%)&#xD;
&#xD;
          -  Platelet count &lt; 100,000/ml&#xD;
&#xD;
          -  Concomitant use of strong CYP 3A inhibitors or inducers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Feng, MD. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Liver Surgery, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chuan Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Liver Surgery, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaosong Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. Liver Surgery, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiang XIA, MD. Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. Liver Surgery, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hao Feng, MD. Ph.D</last_name>
    <phone>+8615000901110</phone>
    <email>surgeonfeng@live.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

